A recent review focused on treating the hepatitis C virus (HCV) to achieve a sustained virologic response (SVR), considered a virologic cure. Achieving SVR reduces liver inflammation, fibrosis, liver cancer risk, and mortality, and improves conditions like cryoglobulinemic vasculitis and non-Hodgkin lymphoma. Initiating treatment in early stages of fibrosis increases long-term survival and reduces disease progression. Specific considerations are necessary for patients with advanced liver disease, post-liver transplantation, or rapid fibrosis progression due to HIV/HCV coinfection. Regular fibrosis assessment is crucial, particularly when treatment is deferred. In summary, the review emphasizes the significant benefits of antiviral therapy in treating HCV, achieving SVR, enhancing life quality, and preventing disease transmission.

Reference: When and in Whom to Initiate HCV Therapy. American Association for the Study of Liver Diseases. Infectious Diseases Society of America. Updated October 24, 2022. Accessed January 1, 2024. https://www.hcvguidelines.org/evaluate/when-whom